A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Momelotinib (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms Simplify 2
- Sponsors Gilead Sciences; Sierra Oncology
- 12 Jul 2019 Trial has been completed in Germany, according to European Clinical Trials Database record.
- 03 Dec 2018 Results presented in the Sierra Oncology media release.
- 03 Dec 2018 According to a Sierra Oncology media release, results from this study are being presented today at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History